Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 93 results:
Author Title [ Type
] Year Filters: Author is Anastasilakis, Athanasios D [Clear All Filters]
(2018). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2009). No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial..
Clin Endocrinol (Oxf). 70(4), 522-6.
(2011). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2018). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2022). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2019). Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study..
Metabolism. 154005.
(2012). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2010). Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone..
J Bone Miner Metab. 28(1), 108-10.
(2020). Obesity, osteoporosis and bone metabolism..
J Musculoskelet Neuronal Interact. 20(3), 372-381.
(2019). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2011). Oxidized low-density lipoprotein and adiponectin levels in pregnancy..
Gynecol Endocrinol. 27(12), 1070-3.
(2009). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2012). Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature..
Hormones (Athens). 11(4), 419-27.
(2013). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2017). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2016). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2021). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2010). Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease..
J Bone Miner Metab. 28(6), 706-12.
(2020). Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough..
J Clin Densitom.
(2009). RANKL inhibition for the management of patients with benign metabolic bone disorders..
Expert Opin Investig Drugs. 18(8), 1085-102.
(2023). The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection..
Osteoporos Int.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2011). Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge..
Curr Opin Endocrinol Diabetes Obes. 18(6), 383-8.
(2010). Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis..
Thyroid. 20(10), 1163-73.
